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Abstract
Retroviral recombination is thought to play an important role in the generation of immune escape and multiple drug
resistance by shuffling pre-existing mutations in the viral population. Current estimates of HIV-1 recombination rates are
derived from measurements within reporter gene sequences or genetically divergent HIV sequences. These measurements
do not mimic the recombination occurring in vivo, between closely related genomes. Additionally, the methods used to
measure recombination make a variety of assumptions about the underlying process, and often fail to account adequately
for issues such as co-infection of cells or the possibility of multiple template switches between recombination sites. We have
developed a HIV-1 marker system by making a small number of codon modifications in gag which allow recombination to
be measured over various lengths between closely related viral genomes. We have developed statistical tools to measure
recombination rates that can compensate for the possibility of multiple template switches. Our results show that when
multiple template switches are ignored the error is substantial, particularly when recombination rates are high, or the
genomic distance is large. We demonstrate that this system is applicable to other studies to accurately measure the
recombination rate and show that recombination does not occur randomly within the HIV genome.
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Introduction
Viral diversity is one of the major obstacles to the successful
eradication of HIV [1,2]. It arises due to the interplay between
mutations introduced by error-prone reverse transcription [3],
high levels of viral turnover [4], retroviral recombination [5] and
strong diversifying selection pressure from the immune system [2].
All retroviruses co-package two RNA genomes into each virion.
Retroviral recombination occurs when the reverse transcriptase
(RT) enzyme switches between co-packaged RNAs during reverse
transcription (reviewed in [6,7]). In HIV, recombination occurs
much more frequently than mutation [8], and is a major
determinant of viral diversification. Within infected individuals,
recombination allows sequential rounds of viral escape of both
antibody and T-cell recognition, resulting in loss of immune
control [9,10]. Furthermore, recombination can both promote
and suppress the generation of multiple drug resistance, by
creating or breaking linkages between drug resistance mutations
[11–16]. Therefore, an accurate measurement of recombination
rates directly within the HIV genome is fundamental to our
understanding of HIV.
Recombination has been studied extensively, by many groups,
and is typically detected by monitoring the linking of marker
points from co-packaged RNA genomes into a single DNA
genome. One popular method of measuring recombination is
through the use of retroviral reporter systems. These systems
measure recombination within a ‘foreign’ gene insert, such as
genes that code for antibiotic resistance proteins, surface protein
markers, and/or fluorescent proteins [8,17–24]. Retroviral
reporter systems have the advantage of being able to readily
quantify a large number of recombination events within the
gene insert. However, in vitro studies show that template sequence
and nucleic acid structure are important determinants of the
recombination process [25,26]. Therefore, measurements of
recombination rates within non-HIV ‘foreign’ gene sequences will
not recapitulate recombination rates within HIV sequence. Other
groups utilize the genetic variation between and within HIV
subtypes, and use sequencing to monitor recombination [8,21,22].
These systems provide the foundation to reveal recombination
events within the HIV genome. However, the use of genetically
divergent RNA templates does not reflect the situation in vivo,
where the vast majority of infected individuals are infected with a
single virus which rapidly diversifies into a viral quasispecies over
the course of infection [27]. The use of divergent RNA sequences
can lead to confounding differences in parameters known to
affect recombination, including: overall RNA homology [28,29],
RNA packaging [30,31], and the amino acid sequence of viral
proteins, such as reverse transcriptase [32–34]. Therefore, the
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most likely reflect the special case of inter-subtype recombination.
Hence, there is a real need to develop a retroviral recombination
system which mimics the recombination that occurs between
closely related, yet genetically distinct, viruses found within an
infected individual.
Recombination is detected by monitoring the linking of marker
points from separate RNA genomes into a single DNA genome.
Regardless of the system in which it is measured, recombination is
either detected or undetected between any two marker points.
This is generally interpreted as one or zero recombination events,
respectively. However, with increasing genomic distance and/or
recombination rate, there is an increased likelihood that there will
be multiple template switches between any two marker points
which go undetected. Consequently, with high rates of recombi-
nation and/or genomic distances between marker points, there is a
greater chance of underestimating recombination rates due to
multiple template switches. These possibilities have been men-
tioned previously [20,24,35,36]. However, there is no current
standard method to calculate recombination rates over multiple
genetic regions of varying lengths that also compensates for the
possibility of multiple template switches between marker points.
Additionally there exists no theoretical estimate for the error when
recombination is measured without compensating for multiple
template switches, as is often the case.
Here, we present a novel experimental method based on limited
codon modification of the HIV genome which does not change the
infectivity of the virus or any viral protein. This allows the
measurement of recombination between closely related genomes
analogous to those found in the quasispecies of an infected
individual. This system measures recombination in different gene
segments, allowing the identification of possible recombination
‘hotspots’, where template switches occur at higher frequencies.
We then develop statistical tools to calculate an ‘optimal
recombination rate’ that reproduces observed recombination
frequencies, taking into account multiple template switches. These
tools demonstrate the error in calculating crude recombination
rates (that do not consider multiple template switches) and
emphasize the necessity for careful data analysis. These tools also
provide the basis to quantify statistical differences in recombina-
tion rates in various regions of the HIV genome, under different
conditions, or infection with different target cells. Finally, our
analysis allows for testing and subsequent validation of some
inherent assumptions and sources of error in the experimental
design. We compare our analytic procedure with previously
published studies and find that our approach avoids some of the
potential pitfalls of using reporter gene inserts.
Results
Modeling the effects of multiple template switches on
the observable rate of recombination
Recombination is measured by analysing the cDNA that results
from infection with non-identical (heterozygous) co-packaged
RNA genomes. The positions in which the RNA genomes differ
are called marker points. Recombination is detected only when the
resulting cDNA contains a mixture of marker points from both
RNA strands. It is tempting to conclude that one template switch
has occurred every time recombination is detected between a set of
marker points, and that no template switches occurred elsewhere.
However, any even number of template switches between two
fixed marker points will lead to us observing no recombination,
and any odd number will result in us observing a single
recombination event (Figure 1A). An important consequence of
this fact is that the probability of observing a recombination event
is a function of the genomic distance between the markers and the
overall recombination rate. We created a model of recombination
which takes into account the possibility of not detecting
recombination events (see Materials and Methods). Our recom-
bination rate calculation (denoted ‘optimal’ recombination rate)
reveals the relationship between the overall recombination rate,
distance between marker points and the probability of observing a
recombination event (Figures 1B and 1C). We show that for each
genomic distance and overall rate of recombination, there is a
unique probability of observing recombination. Furthermore, with
high overall rates of recombination and large genomic distances, it
becomes much more difficult to calculate the recombination rate
accurately. Indeed, these probabilities eventually converge until it
becomes impossible to derive the true rate of recombination
because there is an equal chance of observing or not observing a
recombination event.
Ignoring multiple template switches consistently
underestimates the real recombination rate
To demonstrate the consequences of ignoring multiple template
switches, we utilized a simple equation (denoted ‘crude’ recom-
bination rate calculation): r=c/nl, where r is the rate of
recombination events per nucleotide per round of infection
(REPN), c is the number of template switches detected, n is the
number of sequences, and l is the genomic distance over which
recombination is measured. This crude formula assumes that
between marker points, at most one template switch can occur. To
calculate the theoretical expected error of the ‘crude’ recombina-
tion rate we first use the ‘optimal’ recombination rate equation
(Eq. A) to determine the probability of observing recombination
over different genomic distances. We then use the ‘crude’
recombination rate calculation on these probabilities and find
that this calculation consistently underestimates the real recombi-
nation rate. At an actual recombination rate of 0.001 REPN
(lower than the median recombination rate measured in T-cells in
this study), the calculated crude recombination rate is 9% lower
when measured over a distance of 100 nucleotides, and 37% lower
Author Summary
HIV’s ability to generate and maintain high genetic
diversity leads to multiple drug resistances and evasion
from the immune system, eventually leading to immune
failure and progression to AIDS. HIV maintains this
diversity with a process of mutation (incorrect copying of
genetic information in viral replication) and recombination
(mixing two viral genomes in the creation of viral
offspring). Recombination is generally studied by inserting
genes encoding non-viral fluorescent proteins. However,
recombination in such modified HIV genomes may not
accurately reflect the level of recombination occurring
within a patient infected with HIV. Additionally, recombi-
nation will go undetected in regions where the parental
genomes are identical, and this effect is often ignored. We
have developed a novel experimental system which allows
recombination to be measured between two very closely
related HIV genomes. We have also developed statistical
tools to accurately calculate the recombination rate,
compensating for undetectable recombination in identical
regions of the parental genomes. We show that our
experimental system bypasses some of the pitfalls of
fluorescent recombination experiments and our tools
provide a strong quantitative foundation for future studies
in this area.
Measuring HIV Recombination
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This error is even larger when the real recombination rate is 0.003,
where the crude rate is 25% and 68% lower than the actual rate
when measured over a distance of 100 nucleotides and 500
nucleotides respectively (Figure 1E). This error is a direct result of
not considering multiple template switches, emphasizing the need
for our optimal recombination rate calculation.
Experimental detection of recombination within the HIV
genome
We sought to measure the rate of recombination directly in the
HIV genome. To this end, we made a marker virus (MK) by
introducing 6 codon modifications into the gag gene of wild-type
(WT) HIV. This creates 5 regions (varying in length from 77 to
398 nucleotides) over which we can directly measure the
recombination rate of a full length HIV genome (Figure 2A and
2B). These modifications neither affect the infectivity of the virus
nor alter the amino acid sequence of any viral protein (Figure S1).
The recombination process depends greatly on template sequence,
RNA structure, the overall homology between sequences and the
viral proteins involved in reverse transcription. Therefore, this
system mimics the situation in vivo, where recombination occurs in
the context of a quasispecies of highly related, yet genetically
distinct viruses.
Figure 1. Multiple template switches change the observable
recombination rate. (A) Recombination occurs during reverse
transcription when RT switches from one co-packaged RNA template
to another. Marker sites in one RNA template allow the detection of
recombination. However, the exact number of template switches
cannot be known. That is, recombination is only observed with any odd
number of template switches and recombination is not observed with
zero, or any even number of template switches. (B) The probability of
observing a recombination crossover changes with recombination rate
(measured as ‘‘recombination events per nucleotide per round of
infection [REPN]) and the length over which recombination is observed.
For each length (length in nucleotides of RNA shown below each line),
each recombination rate produces a unique probability of observing a
recombination. (C) Profiles a snapshot of the probability of observing a
recombination over different lengths with a constant recombination
rate 0.001 REPN. (D and E) Using a crude formula for calculating the
recombination rate (r=c/nl, where c is the number of template switches
detected, n is the number of sequences, and l is the distance between
marker sites) that does not take into account multiple template
switches underestimates the actual rate. This error increases with
genomic distance and recombination rate. The probability of observing
recombination is calculated with the Poisson approximation derived in
Materials and Methods (Equation A).
doi:10.1371/journal.pcbi.1000766.g001
Figure 2. Schematic representation of the marker recombina-
tion system. (A)Markerpointswereintroducedbygenetic changesthat
do not alter the amino acid sequence. (B) The distances between marker
points within gag (C) Transfection-induced recombination was measured
by direct sequencing of plasmid DNA extracted from co-transfected 293T
cells (D) PCR-induced recombination was measured by separately
infecting T-cells with homozygous virions derived from single transfec-
tions of WT and MK plasmid. Lysates were mixed before PCR. (E) Inter-
virion recombination and PCR-induced recombination was measured by
infecting T-cells with homozygous virions derived from single transfec-
tions of WT and MK plasmid. (F) The recombination rate in T-cells was
measured by infection of T-cells with virus produced by co-transfection
of 293T cells with WT and MK plasmid. (D,E,F) Recombination rates were
measured by PCR of cellular lysates, cloning and sequencing.
doi:10.1371/journal.pcbi.1000766.g002
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DNA provirus is most likely to be the result of viral recombination
during reverse transcription of the two RNA molecules co-
packaged in a heterozygous virion. However, it is possible that
recombination could also have occurred during a number of steps
in sample preparation and sequencing. To determine the potential
bias within our experimental system, we quantified experimental-
ly-induced recombination, as follows:
Firstly, we tested the possibility of transfection-induced recom-
bination which can occur via homologous recombination in the
producer cell [37]. We measured this by direct sequencing of
plasmid DNA extracted from co-transfected 293T cells (Figure 2C).
Of 182 sequences of plasmid DNA extracted from transfected cells
we observed zero recombination events, suggesting that this is not
a source of error in our system (Table 1).
Secondly, we tested for PCR-induced recombination that may
occur if the polymerase switches templates during PCR amplifi-
cation of the viral sequences prior to sequencing. We measured
this by performing two separate infections with either WT
homozygous virus or MK homozygous virus (Figure 2D). In this
case, recombination occurs at the usual rate between co-packaged
HIV RNA strands, but template switching between these identical
copies of RNA cannot be detected. These homozygous samples
are mixed prior to PCR. Thus, any observable recombination can
be inferred to be an artifact of the PCR. 125 sequences were
obtained and 3 recombination events were detected (Table 1).
Finally, we measured the rate of ‘inter-virion’ recombination that
may have occurred if the target cells were multiply infected, and
retroviral recombination was occurring between the RNA mole-
cules of different virions. To do this we co-infected cells with
homozygous WT and homozygous MK virions. Thus, any intra-
virion recombination would be undetected, but both inter-virion
recombination and PCR-induced recombination would be detected
(Figure 2E). 128 sequences were obtained and 2 recombination
events were detected (Table 1).
To measure the biological rate of recombination we generated a
mixture of heterozygous and homozygous virus by co-transfection.
When equal amounts of two HIV plasmids are co-transfected, co-
packaging of RNA into virions is random [38]. Therefore, when
we co-transfected equal amounts of WT and MK plasmid, we
expect 50% heterozygous virions, 25% homozygous WT virions
and 25% homozygous MK virions (Figure 2F). This mix was used
to infect primary T-cells. 118 sequences were obtained and 58
recombination events were detected (Table 1).
Calculating crude and optimal recombination rates
In determining recombination rates, it is easy to assume that
transfection of equal amounts of WT and MK plasmid leads to the
production of 50% heterozygous and 50% homozygous virus.
However, variations in the level of co-transfection will lead to the
production of a different proportion of heterozygous virions than
expected. This will bias the calculation of recombination rates.
Our design allows us to estimate the proportion of heterozygous
virions in our experiments directly from the data (as described in
Materials and Methods). The estimated proportion of heterozy-
gous virus was approximately 50% in our studies (48.6%, 45.1%,
49.7% and 46.1% for transfection, PCR, between virion and T-
cell experiments respectively), indicating that there is no bias in
infection rates between WT and MK virus or in the production of
our heterozygous virions.
We then calculated the recombination rates for each of our
experimental conditions, using both our crude and optimal
recombination rate calculations (Table 1). As we detected no
recombination events in our transfection-induced recombination
control, the crude and optimal recombination rates were 0 REPN.
From 125 and 128 sequences for the PCR-induced recombination
control and the PCR-induced plus inter-virion control, we observe
3 and 2 recombination events respectively. This corresponds to an
optimal recombination rate of approximately 0.1610
23 REPN.
For our biological sample, the crude recombination rate was
calculated to be 0.81610
23 REPN, and the optimal recombina-
tion rate to be 1.45610
23 REPN. Thus, the crude recombination
rate underestimates the optimal rate by approximately 44%. This
underlines the importance of calculating recombination rates using
our ‘optimal’ recombination rate calculation instead of the ‘crude’
method commonly used in the literature, which does not
compensate for multiple template switches.
Using the above approach we are able to directly estimate the
recombination rate from an experimental data set. However, the
error of this estimate is affected by the number of sequences
sampled, and their distribution. In order to determine confidence
intervals for these estimates we generated probability distributions
by bootstrapping the sequence data (see Materials and Methods).
The 95% confidence intervals of these distributions are calculated
with the Percentile Method and are shown in Table 1. Due to the
high number of samples (.118 for all datasets) and relative
symmetry of the bootstrap distributions (data not shown), we
assume very good coverage of these confidence intervals. We
conclude that the recombination rates are significantly different (at
the 0.05 level) when the 95% confidence intervals do not overlap.
These distributions show that the recombination rate is not
significantly different between PCR induced recombination and
PCR induced plus inter-virion recombination. Thus, inter-virion
recombination is not a significant factor in our experimental setup.
However, recombination rates were significantly different between
our controls and the rate of HIV RT-induced recombination in
Table 1. Crude and optimal recombination rates in T-cells and experimental controls.
Recombination
Experiment
Clones
sequenced
Recombination
events observed
Crude
Recombination Rate
(610
23)
Optimal
Recombination Rate
(610
23)
95% Confidence
(Lower bound)
(610
23)
95% Confidence
(Upper Bound)
(610
23)
Transfection 182 0 0 0 0 0
PCR 125 3 0.069 0.102 0 0.319
PCR+Intervirion 128 2 0.042 0.105 0 0.376
T-cells 118 32 0.814 1.451 0.773 2.738
Experiments were carried out to quantify recombination in T-cells and experimentally induced recombination. DNA from each experiment was cloned and sequenced
and the number of recombination events scored. The crude and optimal recombination rate for each experimental condition was calculated. Sequence data was
bootstrapped to generate 95% confidence intervals.
doi:10.1371/journal.pcbi.1000766.t001
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rate was then calculated with a control correction method (see
Materials and Methods), that is approximately a subtraction of the
two recombination rates. The RT-induced recombination rate
alone is calculated to be 1.35610
23 REPN in primary T-cells.
Calculating the optimal recombination rate per
nucleotide per round of infection (REPN) in fluorescent
protein gene insertion experiments
Our experimental system allows recombination to be measured
between closely related viral genomes. However, most recent
recombination assays involve the insertion of fluorescent proteins
into the HIV genome. In these systems two distinct defective genes,
encoding a fluorescent protein, are inserted into different HIV
genomes. A recombination event that eliminates the deactivating
mutations recreates a functional fluorescent encoding gene.
Recombination can then be measured via FACS analysis of
infected and fluorescent protein expressing cells. This technique is
capable of producing large quantitative datasets and has shown to
be an effective tool to compare recombination rates under varying
conditions. Generally, the extent of recombination in these systems
is measured as a function of the multiplicity of infection (MOI) of
fluorescent protein expressing cells and the MOI of viral infection.
However these calculations are not easily comparable to calcula-
tions made for marker points separated by different genomic
lengths. A clearer approach is to calculate the recombination rate in
terms of ‘recombination events per nucleotide per round of
infection’ (REPN), as this rate allows the prediction of the number
of recombination events that will occur over any length of RNA. To
demonstratehowourrecombinationratecalculationmethodcanbe
applied to fluorescent protein studies, and to make a direct
comparison of these recombination rates to our own, we analysed
the data from Rhodes et al. 2005 [24].
Table 2, 3, 4, and 5 from Rhodes 2005 lists the total number of
cells, infected cells, and green fluorescent protein positive (GFP+)
cells when the recombination is measured over a genomic distance
of 588, 300, 288 and 103 base pairs, respectively. From these ratios
the GFP+ MOI/infection MOI (ratio denoted as M) is calculated.
This ratio represents the probability of a single infection event
resulting in the reconstruction of a functional GFP protein (see
Materials and Methods). Recombination is only detectable from
50% of the virions (those that are heterozygous). Thus, the
probability that a heterozygous infection recreates a functional
GFP is 2M. A functional GFP is only created when the two
inactivating mutations are eliminated via recombination. Howev-
er, the two inactivating mutations being ‘joined’ via recombination
is equally likely. Thus, the probability that a heterozygous
infection results in mosaic cDNA (from a nucleotide sequence
perspective) is 4M. Using equation (A) (Materials and Methods)
with R(L)=4M converts M into the required recombination rate
measured in REPN.
Thus, taking into account the possibility of multiple template
switches, the recombination rates for the data in Rhodes 2005
ranges from 0.49610
23 to 0.97610
23 (table 2). Note that the
calculated optimal recombination rates in Rhodes 2005 are similar
regardless of the genomic distance over which recombination is
measured. This is because our analytical recombination rate
calculation compensates for genomic distance when calculating the
probability of multiple template switches. Our conversion of the
data in Rhodes 2005 to a recombination rate per nucleotide per
round of infection is in line with previous conversions by
Suryavanshi and Dixit [36], who used curve fitting techniques to
estimate an average recombination rate over the different lengths.
The advantage of our technique is that our procedure can be
applied with a standard calculator and requires no curve fitting
experience or software.
Recombination does not occur randomly in the viral
genome.
Crossover sites of the HIV-1 RT may consist of RNA sequence
determinants that direct the RT to switch templates, and it has
been suggested that RNA-RNA interactions can promote
recombination in vitro [28,29]. Unlike systems that measure
recombination over only one region, our experimental design
allows recombination to be studied in five gene segments in gag,
which cover a total genomic distance of 917 base pairs. Our
analytical recombination rate calculation allows us to calculate the
optimal constant recombination rate that best describes our
experimental data and compensates for the possibility of multiple
template switches. This system allows us to determine: (i) if the
variation in recombination along the gene is significantly different
than that expected by random variation (indicating whether
recombination is a random event); (ii) the optimal location for a
recombination rate change (determining the marker point that
separates any recombination ‘hotspots’ and ‘coldspots’); and (iii)
whether a two recombination rate model better describes the
observed experimental recombination data. Together, these
analyses will help us to determine whether recombination occurs
randomly across the viral genome.
We first use a chi-squared goodness of fit test to determine if the
observed frequency of recombination and the expected frequency
(calculated from our optimal recombination rate and compensat-
ing for multiple template switches, equation (B) Materials and
Methods) are significantly different in each gene segment.
Figure 3A profiles the experimentally observed and expected
number of detected template switches that were recorded over the
different sections of gag. The experimental data displays significant
variation from the expected frequencies of recombination to the
observed frequencies (p=0.02) suggesting that recombination
rates vary along the gene segments.
We then adjusted our mathematical model of HIV recombina-
tion to fit two optimal recombination rates along the gene
segment. This was achieved by splitting the gene segment into two,
and calculating each subsegments optimal recombination rate.
The location of the split was optimised along marker positions 2 to
5. We find that the recombination rate is higher towards the
marker site 1 end and lower towards marker site 6. The optimal
Table 2. Calculation of optimal recombination rates from a
retroviral reporter system (Rhodes et al. 2005).
Recombination rate (610
23)
Genomic distance Cell line 1 Cell line 2 Cell line 3
588 0.68 0.56 0.91
300 0.97 0.68 0.76
288 0.75 0.55 0.59
103 0.75 0.49 0.53
The optimal recombination rate can be calculated using equation (A) and
substituting 4M for R(L), where M is the fluorescent protein MOI divided by the
infection MOI (equal to the probability of a single infection event creating a
fluorescent protein expressing cell). Recombination rates are similar when
measured over varying genomic distances illustrating how our analytical
recombination rate calculation calculates the optimal recombination rate
regardless of the genomic distance over which recombination is measured.
doi:10.1371/journal.pcbi.1000766.t002
Measuring HIV Recombination
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(1.95610
23 and 0.49610
23 REPN from sites 1–4 and 4–6
respectively) (Figure 3B). Comparing the dual recombination rate
model to the original model with an F-test did not produce a
significant p value (p=0.30, Figure 3B), indicating that the dual
recombinationrate model didnotfit significantlybettertojustifythe
additional parameters (second recombination rate and switch
location). To address this further, we analyzed a second set of data
and sequenced 192 cDNA strands. Again, we found that
recombination is higher towards marker site 1 and lower towards
marker site 6 (Figure 3C and 3D). However, an F-test comparing
the one and two recombination rate models in this dataset, but this
time applying the same switch location estimated in the first
experiment (one less parameter in the two recombination rate
model), still did not achieve significance (p=0.068). Thus, our data
support a difference in recombination rate across the gene, but was
unable to identify the precise ‘hotspots’ of higher recombination.
The assumption of an equal recombination rate amongst all
sequences predicts that the frequency of multiple recombination
events should be Poisson distributed. However, due to the
possibility of multiple template switches occurring between
markers of varying genomic distances, and the possibility of
varying recombination rate across the gag gene, the frequency of
multiple detectable template switches does not follow a Poisson
distribution. We calculated this distribution to compute the
expected frequency of multiple detectable template switches and
compare this to our experimental results (Figure 4). This
calculation compensates for multiple crossovers and uses the
individual recombination rate observed in each region. Our data
indicates some variation from the expected frequency of multiple
template switches, however this was not significant (p=0.096).
Finally, it is possible that the limited introduction of marker
points into the HIV genome altered the RNA structure in such a
way as to bias the recombination process. For example, reverse
transcription commencing on the MK genome may be more likely
to result in recombination than reverse transcription on the WT
genome due to our codon modifications. This predicts that the
probability of recombination will be different when the RT is
reverse transcribing a WT or MK marker point. Therefore, we
compared the proportion of recombination events where recom-
bination occurred from MK to WT, versus from WT to MK in
our sequences. Of the 90 template switches observed in the pooled
dataset, 42 were MK to WT and 48 were WT to MV, consistent
with the null expectation of 50:50 (p=0.60, binomial distribution).
This illustrates that our codon-modified markers have not
significantly altered the RNA structure so as to bias the observed
recombination rate.
Discussion
Recombination plays an instrumental role in the evolution of
HIV [39,40] and continues to shape the global pandemic [41].
Despite the excellent progress made in understanding inter-
subtype recombination [30,42,43], the study of recombination
occurring between closely related genomes within an infected
individual has been hampered by the lack of an appropriate
Figure 3. HIV recombination varies across genome. An optimal
recombination rate is calculated by minimizing the chi-square value
between the observed and expected frequencies of detectable
template switches in each of the regions. A chi-square goodness of
fit test indicates whether recombination rates are likely to vary over the
entire length. (A) Variation between expected and observed frequencies
(B) A dual recombination rate model was fitted and marker point 4 was
the optimal location for a recombination rate switch. (C, D) In a second
independent experiment we also observe that recombination is higher
towards marker region 1 and lower towards marker region 6. However
an F-test comparing a single recombination rate model (C) and a dual
recombination rate model (D) with the switch location known from the
original experiment, still did not achieve significance (p=0.068, F-test).
doi:10.1371/journal.pcbi.1000766.g003
Figure 4. Frequencies of multiple detected template switches
follows a modified Poisson distribution. The experimental
assumption of an equal recombination rate amongst all sequences
predicts that the frequency of multiple observed recombination events
should be distributed as calculated by rate of recombination in each
region, number of sequences and lengths over which recombination is
measured. Large variation from the expected distribution indicates that
this assumption may not be correct. Data shown is from the two
heterozygous infection datasets combined (310 total sequences)
corrected for control recombination (PCR).
doi:10.1371/journal.pcbi.1000766.g004
Measuring HIV Recombination
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reporter sequences, inter-subtype HIV genomes and/or intra-
subtype HIV genomes with variation in amino acid sequences.
Therefore, we have developed a novel marker system and
associated mathematical tools that: (i) measures the recombination
rate directly on the HIV genome; (ii) controls for background
recombination; (iii) corrects for multiple template switching.
Our HIV recombination marker system uses genetic marker
points based on the codon modification of the authentic full length
HIV genome without altering the amino acid sequences. Other
groups have previously measured recombination rates on the HIV
genome using the divergent RNA sequences found between or
within HIV subtypes or within non-viral reporter sequences. Our
procedure has several advantages over previously published
methods. First, we rationally introduced marker points into the
HIV genome at well defined locations, by avoiding RNA
sequences that are known to be important for HIV replication.
These marker points allow recombination to be monitored, but do
not affect the HIV replication cycle, even over multiple rounds of
replication (Figure S1). This is in contrast to recombination
systems using divergent RNA sequences from different viral
strains, where the differential replication capacities of the virus
may bias the outcome of recombination. Second, our marker
system retains every virion protein and these are expressed in their
correct biological context. In the case of the retroviral reporter
systems, it is common to completely knockout one or more HIV
proteins by replacing them with non-viral reporter protein
sequence. Therefore, these reporter systems, even when attempts
are made to reintroduce these proteins back into the virion, do not
recapitulate the exact biological conditions occurring in the full
length virus [22,24]. Third, our silent modifications do not change
the amino acid sequence of the viral proteins. This is important in
light of reports that the amino acid sequence of the HIV RT
affects the rate of template switching [32,34] and that mutations in
the Gag polyprotein can affect RNA packaging and recombination
[44]. Therefore, it seems likely that variations in the amino acid
sequence of any viral protein involved in either assembly or reverse
transcription of the virus could have unintentional consequences
on the rate of recombination. This would limit the utility of
divergent RNA sequences, even from within the same subtype
[45]. Fourth, by limiting our modifications to targeted regions of
the genome, we aim to maintain overall RNA structure and
homology, which are critical determinants of recombination
[28,29,46]. We demonstrated that recombination occurred at an
equal rate on our WT and MK genome; hence, our modifications
do not change the rate of recombination. This indicates that the
variations in the recombination rate we observe are due to
differences in the RNA sequence between marker points, not to
the marker points themselves.
We acknowledge that there are experimental complexities
associated with the direct measurement of recombination by
sequencing that can lead to the inclusion of non-viral recombi-
nation artifacts. Therefore, we carefully controlled for transfection-
induced recombination, PCR-induced recombination and the
effects of co-infection due to inter-virion recombination. In our
study, transfection-induced recombination can be excluded as a
source of error. We also show that inter-virion recombination, due
to multiple infections of a cell, is not a significant source of error.
By contrast, most retroviral reporter systems are biased by multiple
infections. That is, in most retroviral reporter systems, multiple
infections cannot be distinguished from single infections. This
decreases the apparent total number of infection events, which is
required to accurately calculate the recombination rate. To
overcome this, these systems make use of MOI calculations which
compensates for multiple infections. However, MOI calculations
assume that infection events are independent and random. This is
problematic in light of reports that double-infection occurs more
frequently than predicted from random chance alone [47,48],
although this effect has been challenged by other data [22] and
mathematical analysis [49]. Nevertheless, our system has the
advantage that the recombination rate calculations are not
affected by the occurrence of multiple infections. Finally, we did
detect some recombination due to PCR-induced recombination
but were able to optimize our PCR cycling conditions to minimize
its effects. In addition, our recombination rate calculation corrects
for this background to reveal the true rate of recombination. This
highlights the necessity of including appropriate controls, as the
effect of PCR-induced recombination has been ignored in similar
studies [8,22,50,51].
As recombination is measured by observing the linking of
genetic marker points, all recombination systems are potentially
biased by the occurrence of multiple template switches. A potential
solution is to reduce the genomic distance between marker points
and to evenly space them on the HIV genome. This effectively
eliminates multiple template switches and any bias due to
variations in genomic distance between marker points. However,
it is impossible to modify the HIV genome in this way without
drastically affecting the replication cycle. As a result, modifications
that do not affect important RNA sequences or vary the amino
acid sequences of viral proteins will always be unevenly spaced.
Furthermore, increasing the frequency of marker points increases
the genetic diversity between co-packaged RNAs. This is expected
to decrease the observed recombination rate, as high levels of
sequence identity between templates is required for efficient
template switching [46,52]. Thus, whilst reducing the genomic
distance between markers can improve the ability to detect
recombination, it also biases the observation by decreasing the
likelihood of template switching in the first place. As multiple
template switches between any two marker points occur, by
definition, between identical sequences, these switches take place
under optimal conditions for recombination. Therefore, a better
solution is to compensate for multiple crossovers when calculating
the recombination rate, as we have done.
We also calculate the theoretical estimate for the error when
recombination is measured without compensating for multiple
template switches and show that the width between marker points
can dramatically affect the crude recombination rate estimation.
For example, when the distance between marker points is 400 base
pairs, an actual recombination rate of 0.001 REPN and 0.003
REPN would be crudely calculated to be 0.0007 REPN and
0.0011 REPN, respectively. This is a difference that could be
interpreted as resulting from random variation alone. This effect
becomes more important at higher recombination rates. This is
especially significant as recombination has been reported to be 3-
fold higher in macrophages than in T-cells [22], although this has
been disputed by another group [18]. Regardless, we find that
HIV undergoes 1.35610
23 REPN in primary T-cells, which is a
high rate of recombination, equivalent to 12.5 recombination
events per genome every replication cycle. This is higher than
when we apply our method to the data in Rhodes 2005 [24]
(average recombination rate 0.69610
23). However the measure-
ments in our study are based on the HIV genome rather than non-
viral reporter genes in previous studies [18,22]. The utility of our
optimal recombination rate calculation is demonstrated by the fact
that the crude calculation underestimates the optimal recombina-
tion rate by 44%. In addition, our bootstrapping procedure
determines the confidence intervals of the recombination rate
estimate. As these confidence intervals are derived from the actual
Measuring HIV Recombination
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it enables the direct comparison of recombination rates under
different experimental conditions as well as providing an
additional level of accuracy to our estimation.
Our measurements on the HIV genome demonstrate that
recombination does not occur randomly. Firstly, our results
suggests that two or more recombination events on the same RNA
strand may be observed more frequently than expected, although
this was not statistically significant (p=0.096, Figure 4). This is in
line with previous work showing HIV recombination exhibiting
negative interference, which is when a single recombination event
increases the chance of a second recombination event taking place
[8], although this is not universally agreed upon by all researchers
[18]. Secondly, in two independent datasets (from different blood
donors), the recombination rate appears to be lower towards
marker position 6 compared to position 1 within the gag gene. We
tested whether a dual recombination rate model fitted the data
better, but this did not reach significance at the 0.05 level
(p=0.068). Therefore, the data imply that there are recombina-
tion ‘hot-’ and/or ‘cold-spots’ within the genome but this current
dataset was not large enough to identify how, or precisely where,
the recombination rate changes. Interestingly, comparative
sequence analysis of inter-subtype recombinants also showed a
reduction in recombination near the 39 end of gag [43]. Although
this could be due to selection, our study opens up the possibility
that this region of the genome may be inherently less prone to
recombination. Further studies with much larger sequence
numbers will be required to determine the positions of various
recombination ‘hot/coldspots’, and their respective recombination
rates. The requirement of large quantities of sequencing data is a
major limitation of our analytical tool. However, with the
availability of next generation sequencing technology, plus the
design of a marker system that has more marker points (higher
level of resolution), these issues can be readily accommodated.
We have now developed appropriate statistical tools to quantify
the rate of retroviral recombination taking into account the
experimental procedures involved in observing recombination. We
have shown how this can be used to compare recombination rates
and to identify recombination hotspots within the viral genome.
We also test a number of underlying biological and analytical
assumptions that are often overlooked. These methods take into
account the experimental and biological complexities of measuring
recombination, and will provide a strong quantitative foundation
for future studies in this area.
Materials and Methods
Ethics statement
Human primary cells were isolated from buffy packs from
random (identity blocked) blood donors to the Red Cross Blood
Bank. All biological samples were handled according to the Burnet
Institute and the Alfred Hospital approved ethics guidelines that
are in line with Australian Government regulation.
Viruses
Homozygous virus was produced by transfection of 293T cells
with either WT or MK pNL4-3. Heterozygous virus was pro-
duced by co-transfection of equal amounts of wild-type pNL4-3
and marker pNL4-3 into 293T cells. Transfections were carried
out with polyethylenimine (PEI; Polysciences), and transfection
efficiencies were measured using a reverse transcriptase assay
[53,54]. 36 hours post-transfection, virus containing media was
harvested, clarified by centrifugation at 1,4626g for 30 minutes,
and then passed through a 0.45mm filter to remove cellular
debris. Purified virus was concentrated by ultracentrifugation at
100,0006g through a 20% sucrose cushion and stored at 280uC.
Virus was treated with 90units/mL benzonase (Sigma) for
15 minutes at 37uC to remove contaminating plasmid DNA
before use.
Recombination assay
Stimulated PBLs were infected with equal amounts of either
homozygous or heterozygous virus, as determined by a HIV-1
antigen (p24 CA) micro ELISA assay (Vironostika). Heat
inactivated (2 hours at 56uC) control infections were carried out
to confirm efficient removal of plasmid DNA for each sample.
6 hours post-infection 10mg/mL T-20 (Roche) was added to the
cells to prevent second round replications. 24 hours post-infection
cells were pelleted, lysed and full length reverse transcriptase
products were quantified, as previously described [55]. A 1kb
fragment of gag was PCR amplified using the primers (EcoR-
I)NL3065s [GCAgaattcGAGCTAGAACGATTCGCAG] and
(BamHI)NL4066a [TATggatccTGGATTTGTTACTTGGCT-
CATTG] and the following conditions: initial denaturation 98uC
for 30 seconds, followed by 30 rounds of cycling at 98uC for
10 seconds and 72uC for 2 minutes. PCR amplification was done
in the log-linear phase as determined by real-time PCR to
minimize PCR induced recombination. The fragment was cloned
into pGem7z (Promega) and sequenced using the M13F primer on
an Applied Biosystems 37306l (Australian Genome Research
Facility). Recombination events were identified by sequence
analysis.
Controls were carried out to quantify the background rate of
recombination produced by the experimental protocol itself.
Transfection induced recombination was measured by harvesting
plasmid DNA 36 hours post transfection directly from 293T by
alkaline lysis as in plasmid DNA preparation from bacterial cells
[56]. Plasmid DNA was directly sequenced with NL2944
[AGAGATGGGTGCGAGAG] after isolation by transformation
of E.coli.
Molecular clones
Wild-type HIV-1 pNL4-3 plasmid was obtained from the
National Institutes of Health AIDS Research and Reference
Reagent program, Division of AIDS, NIAID, NIH: pNL4-3 from
Dr. Malcolm Martin [57]. Marker HIV-1 pNL4-3 plasmid was
created through the introduction of six restriction sites in gag by
site directed mutagenesis [58,59], All six sites are codon optimized
and have not changed the protein coding sequence, and are
separated by 128, 77, 86, 398, 228 base pairs (Figure 2A and 2B).
The location of the marker points is determined, in part, by the
limited number of locations on the HIV-1 genome where
restriction sites can be successfully introduced without changing
protein coding sequence.
Cell culture
293T cells were obtained from the American Type Culture
Collection and maintained in DMEM media (Invitrogen)
supplemented with 10% vol/vol CCS (Hyclone) and Pen/Strep
(Invitrogen). Primary human peripheral lymphocytes (PBLs) were
isolated from two independent buffy coats of HIV-1 seronegative
blood donors (Red Cross Blood Bank Service, Melbourne) by
density gradient centrifugation over Ficol-Plaque Plus (GE
Healthcare). PBLs were isolated by counter-current elutriation.
The purity of PBLs was assessed by flow cytometry (FACs Calibur;
Becton Dickinson) and determined to be .95% pure based on
forward scatter and side scatter characteristics. PBLs were
stimulated for 2–3 days in RPMI-1640 (Invitrogen) supplemented
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PLoS Computational Biology | www.ploscompbiol.org 8 April 2010 | Volume 6 | Issue 4 | e1000766with 10mg/mL phytohemagglutinin and transferred into fresh
RPMI-1640 containing 50 units/mL Interleukin-2 (Roche) before
infection.
Estimating the proportion of heterozygous sequences
We co-transfect equal amounts of WT and MK DNA, in order
to produce heterozygous virions. Assuming random co-packaging
of viral RNA templates we expect that 50% of the synthesized
cDNA to have derived from heterozygous sequences. However,
differences in the proportions of the WT and MK sequences may
affect the proportion of heterozygous virions (resulting in incorrect
estimation of recombination rate). We calculate the expected
proportion of heterozygous virions from the experimental data as
follows. Let PW and PM be the proportion of experimentally
observed nucleotide sequence data that is completely WT and MK
respectively. PW and PM represents cDNA derived from homozy-
gous WT and MK virions, and also cDNA derived from
heterozygous virions in which recombination was not observed.
Now let F be the fraction of cDNA derived from heterozygous
virions that did not observe recombination. We then have
PW~w2zFmw
PM~m2zFmw
where w and m are the proportion of WT and MK constructs that
were cotransfected into T cells to create the virions. Noting that
m=1-w allows for solving the expected proportion of cDNA
derived from heterozygous virions, 2mw. Thus, we do not need to
rely on the estimated proportion of WT:MK virus, but can directly
estimate it from our data.
Recombination rate calculation
We measure recombination by infection with two nearly
identical HIV-1 viruses, denoted WT and MK, which differ at a
number of marker positions in gag. Recombination is observed
when a single sequence of DNA product contains both WT and
MK markers. However, multiple template switches can occur
between marker positions, and recombination can only be
detected when there are an odd number of template switches.
Thus, it is impossible to work out the exact frequency of
recombination events. Rather, the data shows the probability of
observing recombination (a switch from WT to MK between
markers or vice versa) which is calculated as the number of
recombination events observed divided by the number of
sequences derived from heterozygous infection. Denote the
probability of observing a recombination event between two
marker positions separated by a genomic distance of L as R(L).
Denote the recombination rate per nucleotide per round of
infection as r. These two quantities then satisfy the following.
R(L)~
X
Lz1
2
  
j~1
C(L,2j{1)r2j{1(1{r)
L{2jz1
where [(L+1)/2] is the integer part of (L+1)/2 and C(L,i) is the
binomial coefficient for picking i unordered outcomes from L
possibilities. Alternatively, when the genomic distance L is
sufficiently large and the recombination rate r is sufficiently
small (as is generally the case with recombination experiments)
the following Poisson approximation holds [36] (see ‘Poisson
approximation’)
R(L)~
(1{e{2rL)
2
which can be re-arranged to calculate the recombination rate as
r&
{ln(1{2R(L))
2L
ðAÞ
Finally if recombination is studied over multiple regions of lengths
L1, L2,L3,…,Lk, then the recombination rate, r, is calculated as the r
value that minimises the chi-square value
x2~
X k
i~1
(Ei{Oi)
2
Ei
ðBÞ
Where Oi and Ei is the observed and expected number of template
switches that is detected in region i respectively. The expected
number of template switches is calculated as the multiple of R(Li)
and the number of heterozygous sequences.
Comparing recombination rates
Probability distributions were generated by bootstrapping the
sequence data as follows. In each bootstrap loop, sequence data
was randomly sampled with replacement until the same number of
sequences that were originally sampled, had been sampled in silico.
From each new sample set the optimal rate of recombination was
calculated as described above. This bootstrapping procedure was
completed 10000 times and pooling each bootstrap loop generates
a probability distribution for the recombination rate, r. Note that
we sampled from the entire sequence pool, and thus this approach
also incorporates the level of uncertainty in the proportion of
heterozygous virus in the sample. The probability distributions of
the recombination rate for different genetic constructs/target cells
was used to compare rates.
The ratio of GFP+ and infection MOIs represent the
probability of an infection event resulting in the
reconstruction of a functional GFP protein.
Let s(n) be the probability that a single cell has been infected n
times with the HIV reporter virus. Let m be the MOI for the HIV
reporter virus. Let pGFP be the probability of a single infection
event resulting in the reconstruction of a functional GFP encoding
region. That is, the probability that an infecting virion is
heterozygous, and that recombination occurred between the two
co-packaged RNAs such that both GFP deactivating mutations are
eliminated. Then, the probability that a single cell has n infections
that reconstitute a function GFP is given by
X ?
i~0
s(nzi)C(nzi,i)pn
GFP(1{pGFP)
i
~pn
GFP
X ?
i~0
s(nzi)C(nzi,i)(1{pGFP)
i
~pn
GFP
X ?
i~0
mnzie{m
(nzi)!
  
(nzi)!
n!i!
  
(1{pGFP)
i
~
pn
GFPmne{m
n!
X ?
i~0
mi(1{pGFP)
i
i!
  
~
pn
GFPmne{m
n!
em(1{pGFP)
~
(pGFPm)
ne{PGFPm
n!
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to the product, pGFPm. Note that C(n+i,i) is the binomial coefficient
for picking i unordered outcomes from n+i possibilities. Thus, the
GFP MOI equals pGFPm and division of the infection MOI, m,
leaves pGFP, the probability that an infection event will reconstitute
a functional GFP encoding region.
Control correction
In this assay, recombination can occur at two independent
stages: The experimentally induced recombination, and the viral
reverse transcription induced recombination. We measure the
experimentally induced recombination alone, and the cumulative
effect of experimentally induced recombination with the reverse
transcription induced recombination. From this we calculate the
reverse transcription induced recombination rate alone as follows.
Let RE(L) and RR(L) be the probability of observing recombina-
tion over a genomic distance of L for the experimentally induced
and RT induced recombination rates respectively. The cumulative
probability of observing recombination after both effects, R(L),i s
given by
R(L)~RE(L)zRR(L){2RE(L)RR(L)
Note that RERR is subtracted once as RE and RR are independent
and not mutually exclusive events, and subtracted a second time to
eliminate the cases where PCR template switch nullifies an RT
template switch. This is then re-arranged to give
RR(L)~
RE(L){R(L)
2RE(L){1
The recombination rate is calculated from equation (A). If
recombination is measured over multiple regions, as is the case
in our experimental system, this should be applied to each region
before calculating the recombination rate by minimizing the chi-
square value (equation B).
Poisson approximation
The binomial terms Pi(L) above can be approximated by the
Poisson distribution when the length, L, is sufficiently large, and
the recombination rate, r, is sufficiently small. Under these
conditions the Poisson coefficient is the product of the genomic
length and recombination rate Lr. The probability of observing
recombination is then approximated by
R(L)&
X
Lz1
2
  
j~1
(rL)
2j{1e{rL
(2j{1)!
&e{rL X ?
j~1
(rL)
2j{1
(2j{1)!
~e{rL (erL{e{rL)
2
~
(1{e{2rL)
2
Thus, to calculate the recombination rate r from experimental
data we re-arrange to give
r&
{ln(1{2R(L))
2L
where R(L) can be measured from experimental data as the
proportion of heterozygous sequences over which recombination
was observed.
Supporting Information
Figure S1 (A) Replication kinetics of WT and MK virus.
Equivalent levels of virus, as determined by a micro-RT assay,
were added to 2610
5 PHA stimulated PBMCs in triplicate. Seven
10-fold serial dilutions of each virus, and a no virus control were
tested in triplicate. Supernatants were collected on days 3, 7, 10
and 14 post-infection and viral production was measured using a
micro-RT assay. (B) Protein processing profiles of cellular and
virion lysates. 293T cells were transfected with WT and MK
plasmid. 36 hours post-transfection, cells were washed twice in
DPBS and pelleted at 1,4626g for 10 min at 4uC. Viral particles
were purified and concentrated by ultracentrifugation through a
20% sucrose cushion using a Beckman ultracentrifuge L-90 model
(SW 41 rotor) at 100,0006g for 1 h at 4uC. Cell and virion pellets
were lysed in TBS lysis buffer (50 mM Tris-HCl [pH7.4],
150 mM NaCl, 1% vol/vol NP-40, 20 mM phenylmethylsulfonyl
fluoride (PMSF), 1 mM pepstatin, and 1 mM leupeptin) at a
concentration of approx 1610
7 cells or 40 mg of p24 per mL. Cell
lysates were rapidly freeze-thawed three times to weaken the
cellular membrane and cell debris was subsequently removed by
centrifugation at 20,0006g for 30 min at 4uC. Lysates were mixed
with 56 loading buffer (100 mM Tris-HCl [pH 6.8], 1.6% b-
mercaptoethanol, 3% SDS, 33% glycerol and 0.3% bromophenol
blue), incubated at 95uC for 5 min and resolved by SDS
polyacrylamide gel electrophoresis (SDS-PAGE). Resolved pro-
teins were transferred to a nitrocellulose membrane (Amersham).
The membrane was incubated for 30 min in blocking buffer (5%
wt/vol skim milk, 50 mM Tris-HCl [pH7.4], 150 mM NaCl) at
room temperature. Proteins were identified using pooled HIV-1
seropositive patient sera.
Found at: doi:10.1371/journal.pcbi.1000766.s001 (1.52 MB TIF)
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